Grant: Research Tools and Instruments - Category 1 (<$150,000)
University of Alberta
$79,600.00
A Digital PCR for Biomedical Engineering Research
EF 2012-13
Résumé
Probing mechanisms of action and improving the performance of therapeutic agents are indispensable part of developing new and innovative therapeutic interventions. Evaluating the performance of therapeutic agents with polymerase chain reaction (PCR) is ideal in genetic therapies since it is cost effective and provides an optimal system to follow the fate of delivered agents as well as their effect. The PCR analysis, however, have been qualitative and provided 'relative' (not absolute) information on investigated systems. The conventional PCR could also become expensive if analysis is conducted one at a time. Recent technologies advances have created a new approach to PCR, so called digital PCR (d-PCT), where analytes are dispersed into small volumes and actual number of analyte is determined in a given sample. This new approach will allow us to probe the quantitative levels of delivered agents and provide answers in 'absolute' terms. It will allow better engineering analysis of therapeutic responses and more rapid optimization of therapeutic agents. This project is intended to acquire a state-of-the-art d-PCR for this purpose. This instrument will enhance our research capability by providing valuable information about our therapeutic approaches, and expedite our research activity by making a vital tool available continually for our research. It will quicken the pace of our research and provide a more comprehensive evaluation of therapeutic agents intended for human use.
Programme
Research Tools and Instruments - Category 1 (<$150,000)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
439808-2013
Name nom
Uludag, Hasan
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2013
Award amount
79600
Program id
EQPEQ
Program name en
Research Tools and Instruments - Category 1 (<$150,000)
Program name fr
Outils et instruments de recherche - catégorie 1 (<150 000$)
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
A Digital PCR for Biomedical Engineering Research
Keyword
NSERC
Application summary
Probing mechanisms of action and improving the performance of therapeutic agents are indispensable part of developing new and innovative therapeutic interventions. Evaluating the performance of therapeutic agents with polymerase chain reaction (PCR) is ideal in genetic therapies since it is cost effective and provides an optimal system to follow the fate of delivered agents as well as their effect. The PCR analysis, however, have been qualitative and provided 'relative' (not absolute) information on investigated systems. The conventional PCR could also become expensive if analysis is conducted one at a time. Recent technologies advances have created a new approach to PCR, so called digital PCR (d-PCT), where analytes are dispersed into small volumes and actual number of analyte is determined in a given sample. This new approach will allow us to probe the quantitative levels of delivered agents and provide answers in 'absolute' terms. It will allow better engineering analysis of therapeutic responses and more rapid optimization of therapeutic agents. This project is intended to acquire a state-of-the-art d-PCR for this purpose. This instrument will enhance our research capability by providing valuable information about our therapeutic approaches, and expedite our research activity by making a vital tool available continually for our research. It will quicken the pace of our research and provide a more comprehensive evaluation of therapeutic agents intended for human use.